MONTREAL – June 2nd, 2021 – Soundbite Medical Solutions Inc. (SBMS), a medical device company dedicated to developing solutions for the interventional treatment of calcific peripheral and coronary arterial diseases, today announced the use of its novel Active Wire 0.014” platform at a first site in the United States in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified lower limb chronic total occlusions (CTO).
The Active Wire was used in procedures at the UNC REX Hospital (NC) by Dr. George Adams, MD, MHS, FACC, Director, Cardiovascular and Peripheral Vascular Research; Associate Professor, Cardiology, UNC School of Medicine. “Peripheral Artery Disease (PAD) and CLI in particular are a threat to life and limb. Our early experience with the 0.014” platform of the SoundBite® Crossing System in eight (8) patients with severely calcified disease shows impressive CTO crossing efficacy coupled with safety and simplicity. In several cases, crossing and treatment would not have been possible with standard techniques. With an increased demand for devices to aid in treatment algorithms for calcific plaque morphologies, we look forward to building on our experience with the system. The broader introduction of the Soundbite system holds promise to be game-changing in treating calcified CTOs and enabling better treatment outcomes in a difficult-to-treat patient population suffering from PAD and CLI,” commented Dr. Adams.
High calcium burden is present in up to 50% of PAD patients with severe claudication and in >65% of patients with CLI, especially in difficult to treat below-the-knee (BTK) disease. CTOs are encountered in up to 50% of PAD and CLI patients1,2. Within the first year of CLI diagnosis, 25% of patients die and 25% will have a major limb amputation as primary treatment, at a cost of $22 billion in the US alone3,4,5. Successful revascularization significantly reduces the need for amputations.
“We are excited by the strong results we are seeing with our Active Wire in severely calcified peripheral lesions and look forward to the day when our unique technology platform and devices become the standard of care for all difficult-to-treat peripheral vascular lesions worldwide,” commented Lori Chmura, President and CEO of Soundbite.
The SoundBite® Crossing System – Peripheral (SCS-P) consists of the reusable SoundBite® Console, a single-use sterile SoundBite® Active Wire, and their respective accessories. SCS-P leverages Soundbite’s proprietary method to produce and safely deliver shock waves via guidewire platforms to selectively “micro-jackhammer” through calcified lesions. SCS-P is now approved in major markets with CE mark, FDA (510(k)) clearance, and Health Canada approval in both 0.018” and 0.014’’ platforms.
About Soundbite Medical Solutions
Soundbite is a privately-held medical device company uniquely dedicated to developing meaningful solutions for the interventional treatment of calcific peripheral and coronary arterial diseases. Soundbite has developed and deployed a proprietary method to produce and safely deliver shock waves to calcified lesions using an array of guidewire-based devices to improve and transform the standard of care for treatment of patients suffering from calcified and occlusive cardiovascular disease. www.soundbitemedical.com
For information on Soundbite Medical Solutions, please contact: Ashkan Haghighat, PhD, Chief Business Officer, Soundbite Medical Solutions, 2300 Alfred Nobel, Montreal Québec H4S 2A4 (email@example.com).
- Murabito JM et al. Am Heart J. 2002;143(6):961–965. [PubMed] [Google Scholar]
- Fanelli, J Cardiovasc Surg 2014
- Abu Dabrh AM, et al. J Vasc Surg. 2015;62(6):1642–1651. [PubMed] [Google Scholar]
- Norgren L, et al. J Vasc Surg. 2007;45(suppl S):S5–S67. [PubMed] [Google Scholar]
- The SAGE Group
Forward-Looking Statements This press release contains forward-looking statements and forward- looking information, or, collectively, forward-looking statements, within the meaning of applicable securities laws, that are based on our management’s belief and assumptions and on information currently available to our management. You can identify forward-looking statements by terms such as “may”, “will”, “should”, “could”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate” or the negatives of these terms, or variations of them. Forward-looking statements are based upon a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond SoundBite Medical Solutions Inc.’s control that could cause actual results to differ materially from those that are disclosed in or implied by such forward-looking information. The reader is cautioned to consider these and other risks and uncertainties carefully and not to put undue reliance on forward looking statements. Forward- looking statements reflect current expectations regarding future events and speak only as of the date of this press release and represent our expectations as of that date. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances.